CNS Control of Glucose Metabolism: Response to Environmental Challenges [PDF]
, 2013 Over the last 15 years, considerable work has accumulated to support the role of the CNS in regulating postprandial glucose levels. As discussed in the first section of this review, the CNS receives and integrates information from afferent neurons ...
Arble, Deanna M., Sandoval, Darleen A.
core +1 more source
Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials [PDF]
, 2017 Aim: To undertake a systematic review and meta-analysis of randomized controlled trials of the effect of Glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) concentrations. Method: PubMed-Medline, SCOPUS, Web
Ferns, Gordon A +3 more
core +1 more source
Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]
, 2018 In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A +8 more
core +2 more sources
Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]
, 2016 Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core +1 more source
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Quality in Sport: Obesity is a chronic and insidious disease that represents a significant global. The World Health Organization has announced that almost 60% of European adults are overweight or obese.
Michal Rabenda +6 more
doaj +1 more source
Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]
, 2019 The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K +3 more
core
Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]
, 2016 Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst +63 more
core +3 more sources
Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine [PDF]
, 2019 Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control, it is often necessary to rely on combination therapy of multiple drugs or insulin because uncontrolled ...
Andreozzi, F, Mannino, Gc, Sesti, G
core +1 more source
Retatrutide-Induced Intractable Diarrhea
Annals of Internal Medicine: Clinical CasesGastrointestinal symptoms accompanying the use of glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide receptor-GLP-1 receptor co-agonists have been extensively catalogued.
Opeyemi Komolafe
doaj +1 more source
, 2020 The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4.
openaire +1 more source